EUVIMEDEUVIMED entdecken
Crossref

Novel Midkine Inhibitor Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma

Kodcharat Cheevapruk, Mikinori Ueno, Prin Sungwan, Gunya Sittithumcharee, Ryusho Kariya, Somponnat Sampattavanich, Seiji Okada

Anticancer Research · 2024

DOI: 10.21873/anticanres.16897 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Kodcharat Cheevapruk und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma. Die Arbeit wurde bisher 10-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: Multiple myeloma (MM), the second most common hematological malignancy, is characterized by the accumulation of malignant plasma cells within the bone marrow. Despite various drug classes for MM treatment, it remains incurable, necessitating novel and efficacious agents. This study aims to explore the anti-cancer activity of a midkine inhibitor, iMDK (C21H13FN2O2S), in myeloma cell lines. MATERIALS AND METHODS: This study assessed the antiproliferative activity using the MTT assay. Cell cycle and apoptosis were evaluated using flow cytometry. To further investigate the inhibitory mechanism, western blotting was used to detect cell cycle-related proteins, pro-apoptotic proteins, and anti-apoptotic proteins. RESULTS: iMDK inhibits MM cell proliferation in a dose- and time-dependent manner, inducing cell cycle arrest and apoptosis. The reduction in Cdc20 expression by iMDK treatment leads to G2/M phase cell cycle arrest. Furthermore, iMDK down-regulates anti-apoptotic proteins (Bcl-2, Bcl-xL, Mcl-1, and c-FLIP), thereby activating both intrinsic and extrinsic apoptosis pathways. CONCLUSION: iMDK could be a potential candidate for MM treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaHumansMidkineCell Line, TumorApoptosisCell Cycle CheckpointsCell CycleProto-Oncogene Proteins c-bcl-2Cell Cycle ProteinsCell Proliferation

Stichwörter der Autor:innen

Multiple myelomaapoptosiscell cyclemidkine inhibitor (iMDK)

Substanzen

MidkineProto-Oncogene Proteins c-bcl-2Cell Cycle Proteins

Autor:innen und Institutionen

  • Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan.
  • Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.
  • Department of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Graduate School of Fisheries and Environmental Studies, Nagasaki University, Nagasaki, Japan.
  • Division of Hematopoiesis, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto, Japan; okadas@kumamoto-u.ac.jp.

Zitieren

APA

Cheevapruk, K., Ueno, M., Sungwan, P., Sittithumcharee, G., Kariya, R., Sampattavanich, S., & Okada, S. (2024). Novel Midkine Inhibitor Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma. Anticancer Research. https://doi.org/10.21873/anticanres.16897

Vancouver

Cheevapruk K, Ueno M, Sungwan P, Sittithumcharee G, Kariya R, Sampattavanich S, et al. Novel Midkine Inhibitor Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma. Anticancer Research. 2024. doi:10.21873/anticanres.16897

BibTeX
@article{Cheevapruk2024,
  author = {Cheevapruk, Kodcharat and Ueno, Mikinori and Sungwan, Prin and Sittithumcharee, Gunya and Kariya, Ryusho and Sampattavanich, Somponnat and Okada, Seiji},
  title = {Novel Midkine Inhibitor Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.16897}
}
Kostenlos starten →